Regeneron Pharmaceuticals, Inc.
REGN
$638.88
-$3.71-0.58%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -10.08% | -7.97% | 8.91% | -2.84% | 12.01% |
| Total Depreciation and Amortization | -2.92% | 14.72% | 12.33% | 11.93% | 11.22% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 1,055.22% | -42.58% | -462.50% | 46.85% | -108.52% |
| Change in Net Operating Assets | -71.84% | 106.83% | 1,078.09% | 74.91% | -70.58% |
| Cash from Operations | 3.23% | -7.29% | 25.36% | 223.28% | -30.90% |
| Capital Expenditure | -0.57% | -24.60% | 16.74% | -21.33% | -71.25% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | 97.39% | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -122.62% | -16.45% | 40.30% | -123.33% | 156.45% |
| Cash from Investing | -166.24% | -37.16% | 29.86% | -96.34% | 138.38% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 169.14% | 453.91% | -84.18% | -92.80% | -91.12% |
| Repurchase of Common Stock | 17.04% | 2.89% | 22.02% | -16.53% | -64.68% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -4.26% | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | 100.00% | -- | -- |
| Cash from Financing | 26.35% | 31.30% | -13.23% | -135.98% | -2,412.53% |
| Foreign Exchange rate Adjustments | -250.00% | 57.14% | -150.00% | 233.33% | 220.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -125.35% | 27.95% | 495.10% | -58.07% | 571.88% |